Targeted Therapy

Targeted Therapy

If you have been NEWLY DIAGNOSED  START HERE 

Video Library

,
,
,
,
The Global Resource for Advancing Cancer Education (GRACE), in partnership with Georgetown University Hospital is pleased to present the videos from the panel discussion "2017 Advances in Immunotherapy: What Lung Cancer Patients Need to Know".
Cancer Journey:
Cancer Type:
Dr. Vamsidhar Velcheti with the Cleveland Clinic joined GRACE to discuss updates to our Lung Cancer Video Library. In this video, Dr. Velcheti discusses MET as a target in advanced non-small cell lung cancer.
Cancer Journey:
Cancer Type:
Nathan Pennell, MD, PhD, Director of Lung Cancer Medical Oncology at the Cleveland Clinic Taussig Cancer Center in Cleveland Ohio discusses new options in acquired resistance for ALK positive non-small cell lung cancer (NSCLC).
Cancer Journey:
Cancer Type:
Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses current standards for Molecular Testing At Initial Diagnosis Of Advanced Non-Small Cell Lung Cancer (NSCLC).
Cancer Journey:
Cancer Type:
Disease Learning:
,
,
Download the speaker presentations and handouts from the Targeted Therapies Patient Forum in Cleveland at the Taussig Cancer Center on September 16, 2017.
Cancer Type:

Articles

With positive trials of two immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab), in second line NSCLC and compared with...
Cancer Journey:
Cancer Type:
Yesterday, news that the Checkmate 026 trial that compared the PD1 checkpoint inhibitor Opdivo (nivolumab) to standard chemotherapy as first line...
Cancer Journey:
Cancer Type:
Probably the most immediate potentially practice-changing presentation from ASCO was the Japanese J-ALEX study in the subset of about 4-5% of...
Cancer Journey:
Cancer Type:
For patients with an activating EGFR mutation and who develop “acquired resistance”, the pattern of progression that occurs after a sometimes long...
Cancer Journey:
Cancer Type:
Disease Learning:
Dr. Edward S. Kim from the Levine Cancer Institute in Charlotte, NC discusses the feasibility of molecular marker testing and targeted therapy in the adjuvant or post-operative setting.
Cancer Journey:
Cancer Type:

Community Forum

No Result Found